The drug giants moved in near-perfect synchronicity, raising prices for their top-selling arthritis treatments as though they were opposite-corner gas stations bumping up the price of unleaded.
FDA Commissioner Scott Gottlieb calls “patent thickets,” claiming multiple patents for a single drug to build protection from competitors.
“The administration understands … PBMs are part of the solution,” Merritt said.
PhRMA was one of AAN’s biggest donors the previous year, giving it $6.1 million, federal regulatory findings show
JC Scott (00:08): Welcome to the Pharmacy Benefit, a podcast where we talk about issues impacting patients, consumers, and affordable access to prescription drugs and better healthcare through the work being done by pharmacy benefit managers or PBMs. I’m
Though drug makers continue to raise prices out of proportion to increases in value, PBMs are doing their job by keeping drug costs down
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
President MedImpact Healthcare Systems, Inc. Dale Brown serves as President of MedImpact, the nation’s largest independent pharmacy benefit manager committed to putting clients and consumers first, always. In this capacity, Brown is responsible for strategy and operations in the US
©2024 PCMA. All Rights Reserved.
